Thoraflex Hybrid
Vascutek, Ltd. · Decision date Apr 20, 2026
What did the FDA approve?
FDA records P210006/S017 as a supplement to PMA P210006, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 20, 2026.
FDA approval order statement
Approval for extension of shelf-life to 3-years
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 20, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P210006/S017
- Regulatory pathway
- PMA supplement
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- Decision code
- APPR
- Decision date
- Apr 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210006 · Original PMA
Thoraflex Hybrid
P210006/S013 · Related supplement
Thoraflex Hybrid
P210006/S014 · Related supplement
Thoraflex Hybrid
P210006/S015 · Related supplement
Thoraflex Hybrid
P210006/S017 received
Application receipt date recorded by FDA.
P210006/S016 · Related supplement
Thoraflex Hybrid
P210006/S017 · FDA decision
Real-Time Process
P210006/S019 · Related supplement
Thoraflex Hybrid
P210006/S018 · Related supplement
Thoraflex Hybrid
Timeline entries are records held by MedtechLedger for P210006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Thoraflex HybridP210006 | Vascutek, Ltd. | PMA approval | Apr 19, 2022 | FDA |
Thoraflex HybridP210006/S013 | Vascutek, Ltd. | PMA supplement | Jul 30, 2025 | FDA |
Thoraflex HybridP210006/S014 | Vascutek, Ltd. | PMA supplement | Oct 16, 2025 | FDA |
Thoraflex HybridP210006/S015 | Vascutek, Ltd. | PMA supplement | Oct 29, 2025 | FDA |
Thoraflex HybridP210006/S016 | Vascutek, Ltd. | PMA supplement | Jan 29, 2026 | FDA |
Thoraflex HybridP210006/S019 | Vascutek, Ltd. | PMA supplement | Jun 24, 2026 | FDA |
Thoraflex HybridP210006/S018 | Vascutek, Ltd. | PMA supplement | Sep 8, 2026 | FDA |
Explore the linked device profile
Other records with product code QSK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AMDS Hybrid ProsthesisP250055 | Artivion, Inc | PMA approval | Jun 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vascutek, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Newmains Ave., Inchinnan, PA49RR
Sources and methodology
- Original FDA record: P210006/S017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





